WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

The Tracker / July 2026 / K260973

510(k) cleared

InferOperate Suite

Beijing Infervision Healthcare Medical Technology Co., Ltd. · Jul 7, 2026 · K260973

FDA cleared the InferOperate Suite from Beijing Infervision Healthcare Medical Technology Co., Ltd. on Jul 7, 2026 under K260973, a traditional 510(k). The device falls under product code QIH, Automated Radiological Image Processing Software, regulated at 21 CFR 892.2050 as a Class 2 device. The review panel was Radiology.

FDA logged the submission as received on Mar 24, 2026. The decision came 105 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.

Beijing Infervision Healthcare Medical Technology Co., Ltd. has 2 other decisions in the tracker over the last 12 months: K252261 (InferCare RECIST), K250237 (InferOperate Suite).

Questions & Answers

What did FDA clear under K260973?

K260973 is the FDA 510(k) for InferOperate Suite, submitted by Beijing Infervision Healthcare Medical Technology Co., Ltd.. FDA's decision date was Jul 7, 2026, under product code QIH (Automated Radiological Image Processing Software).

Who makes the InferOperate Suite?

Beijing Infervision Healthcare Medical Technology Co., Ltd., based in Beijing, is the applicant of record for K260973.

How long did the K260973 review take?

FDA received the submission on Mar 24, 2026 and issued its decision on Jul 7, 2026, 105 days later.

← All decisions in July 2026

Sources